Large, multicenter, retrospective study of Colombian dialysis patients indicates cardiovascular events were 35% lower for patients on HDx therapy enabled by Theranova than participants on standard hemodialysis1
Data from the study also show HDx therapy may reduce hospitalization rates up to 18%1
DEERFIELD, Ill., -
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study “Effectiveness of medium cut-off versus high flux dialyzers: An inverse probability weighting cohort study,” [Abstract #MO880] was an oral presentation at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, June 5-8, 2021.
Theranova was designed to deliver HDx therapy, which filters a wider range of molecules from the blood than traditional hemodialysis (HD) filters by targeting effective removal of conventional (500 Da to 25 kDa) and large middle molecules (25 kDa to 45 kDa), 2,3,4 allowing for filtration closer to that of the natural kidney. 5,6 These large middle molecules may be associated with inflammation and cardiovascular disease in patients with kidney failure.2,3,4
“Innovation is fueled by continued scientific study and exchange through meetings like the 58th ERA-EDTA,” said Peter Rutherford, M.D., senior medical director, Baxter Renal Care business. “These new findings support a growing library of evidence that kidney disease patients on HDx therapy enabled by Theranova may experience improved clinical outcomes and lower healthcare resource utilization.”
The new data are from an observational, multicenter, retrospective cohort analysis of more than 1,000 adult prevalent hemodialysis patients followed for up to two years at Baxter Renal Care Services clinics in Colombia. Weighted incidence rate ratios (IRRs) and rates and duration of hospitalization and cardiovascular events according to dialyzer type were obtained using binomial negative regression with the weighting sample. Hospitalization rates and hospitalization days were recorded over two years. While lower hospitalization rates and cardiovascular events were found in association with HDx therapy enabled by Theranova, no differences in hospitalization duration or survival were identified. Randomized clinical trials are needed to confirm the observed effect.
Theranova is currently used in more than 40 countries, including the United States where it was granted a De Novo application. By granting a De Novo, the U.S. Food and Drug Administration (FDA) established a new classification of dialyzer technology with unique performance standards. The U.S. FDA utilizes the De Novo pathway for low and moderate risk medical devices that have no existing predicate in the United States; such designations are rare in the dialysis space.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Rx Only. For safe and proper use of this device, refer to the Instructions for Use.
This release includes forward-looking statements concerning Theranova, including potential benefits associated with its use (including a reduced incident of cardiac events and hospitalization rates). The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter and Theranova are registered trademarks of Baxter International Inc.
1Molano A. et al. “Effectiveness of medium cut-off Vs high flux dialyzers: An inverse probability weighting cohort study” Abstract presented at the 58th ERA-EDTA Congress. 2021. [MO880]
2Hutchison CA, et al. The Rationale for Expanded Hemodialysis Therapy (HDx). Contrib Nephrol. 2017; 191:142-52.
3Neirynck N, et al. An update on uremic toxins. Int Urol Nephrol. 2013; 45:139-50.
4Duranton F, et al. European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul; 23(7):1258-70.
5Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. Int J Artif Organs. 2017; 40(7):328-334
6Boschetti-de-Fierro A, et al. MCO membranes: Enhanced Selectivity in High-Flux Class. Scientific Reports 2015; 5:18448.